Trial Profile
A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Seagen
- 07 Apr 2021 Status changed from active, no longer recruiting to completed, as per Results published in the Blood
- 07 Apr 2021 Results published in the Blood
- 19 Apr 2020 Planned End Date changed from 1 Dec 2020 to 31 Oct 2021.